1

MaRS | May 15, 2009Thomas G. Wellner – President & CEO

Dr. David N. Bell – VP Drug Development & CSOwww.therapurebio.com

2

13/ of all newproducts

The future of medicine

2

3

$51B

$87B

$25B

$89B

2001

Protein therapeutic market

2005 2010 2010

Worldwide mobile technology market

4

You discovered a protein with blockbuster potential

Specific

Safe

Targeted

Efficacious

Novel

4

5

Ultimately, to get your product approved you will invest…

You are working hard to develop it

5

11 years 5 clinical

trials 2,000

patients 39 patents ~$1 billion

66

What about manufacturing?

What about manufacturing?

7

Discovery Development

Marketing Manufacturing 7

8

Scaling up is not easy

Simple

Quick

Inexpensive

Milligrams

commercialbench

Complex

Long lead times - 4-5 years

Expensive -

$150+ million

Kilograms8

9

Therapure Biopharma:Overcoming the manufacturing barrier

Complex We know protein purification

Long lead times Ready to go now

Quality cGMP compliant

Expensive Established Meadowpine Facility

Regulated We have 8 INDs under our belts

9

10

Committed to the development, manufacture, purification, and packaging of high-quality biological therapeutics

10

Therapure Biopharma Inc.

• Flexible, modern cGMP manufacturing facility

• Expertise in manufacturing & downstream purification

• Extensive quality systems• Deep understanding of

advanced biology & complex proteins

• Creative partnering options

11

Therapure Biopharma – Key Facts

Company Established

• Assets of former Hemosol business acquired Q3/2007 including modern and flexible Health Canada approved facility

• Therapure Biopharma Inc. launched Q3/2008

Ownership Financing

• Privately held by Catalyst Fund Limited Partnership II, a Canadian based private equity fund, and management

12

Modern and Flexible Facility

Facility Built: 2003

Size: 130,000 ft2 (12,000 m2)

Location: Toronto, Canada (Mississauga)

Minutes from Toronto’s Lester B.Pearson International Airport

Employees: 65

Capabilities

• Development, manufacture and fill/finish of therapeutic proteins

• Product development

• Process development

• Manufacturing

• Fill/finish

• Lyophilization

Designed to meet U.S. FDA, Health Canada and EMEA requirements

13

Our Business Strategy

CornerstoneCDMO Business

Unique & Flexible Facility

Scientific & Biomanufacturing

Expertise

Creative Financing

Develop Products-TBI Pipeline

-Joint Venture

14

Key Milestones

Therapure Biopharma Inc. established July/08

Manufacturing plant re-validated Sept/08

Key talent retained and hired

Plant upgraded to create flexible multi-use facility Dec/08

Several key partner/client agreements executed

Revenue generation in 2008

Break even goal in 2009

Business development activities increasing

Pipeline milestones achieved for core assets

Health Canada re-certification of plant – May/09

15

Key Clients / Global Collaborations

Client project opportunities continue to grow

Rare protein development project Growth factors for stimulating bone regeneration

Iron Chelating Agent for thalassemia

PEGylated biologic oncology product

1616

Experienced Sr. Management Team

• Thomas Wellner President and CEOEli Lilly & Co.

• Dirk Alkema, Ph.D.Vice President, OperationsConnaught Labs and Hemosol

• Peter Winkley, CA Vice President Finance and CFOMDS and Ernst & Young

• David Bell, Ph.D. Vice President, Drug Development and CSOBioChem Therapeutic Inc and FAA

1717

Sophisticated Biologic Development &Manufacturing Services

Sophisticated Biologic Development &Manufacturing Services

18

Integrated Full Service Provider

• “One stop-shop” for development and manufacture of therapeutic proteins

• Cost-effectively manage all aspects of development and manufacturing at both small (mg) and large (kg) scale:– Upstream processing– Downstream processing– Clinical supplies including distribution– Commercial manufacturing– Fill and finish– Lyophilization– Full analytical support

19

Fully Integrated Services

Upstream Processing Molecular biology Cell line creation &banking Mammalian cell culturesDownstream Processing• Protein modification• Purification• Stabilization

mg to kg scale batches Preclinical scale Clinical scale Commercial scale

• Aseptic filling of glass vials & preformed bags• Lyophilization• Clinical supplies including distribution

CommercialProduct

20

High Quality Manufacturing Facility

Chromatography Analytical Laboratory

Vial filling line Buffer farm

2121

Support Beyond Development & Manufacturing

22

Creative Financing Opportunities

Therapure can potentially offer creative financing to partners who require development and biomanufacturing services:

Secured DebtEquity partnershipJoint Venture

23

Your trusted partner for protein development & manufacturing

Your trusted partner for protein development & manufacturing

23www.therapurebio.com